Hikal Limited has informed the Exchange regarding a press release dated May 14, 2025, titled "Earnings Press Release on the Results of the Company for the quarter and Financial year ended March 31, 2025".
HIKAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Hikal Limited announced its audited results for Q4 and full year ended March 31, 2025. Q4FY25 consolidated revenue stood at Rs 552 crore with EBITDA of Rs 123 crore (22.4% margin) and PAT of Rs 50 crore. For the full year FY25, revenue was Rs 1,860 crore and EBITDA Rs 328 crore at 17.7% margin. The Pharmaceuticals division posted Rs 351 crore revenue and Rs 55 crore EBIT, while Crop Protection posted Rs 201 crore revenue and Rs 36 crore EBIT, with both segments showing strong sequential growth. The Board recommended a final dividend of Rs 0.80 per share (40%), taking total FY25 dividend to Rs 1.40 per share (70% of face value). Net debt-to-equity improved from 0.67 to 0.59, and ICRA maintained its long-term credit rating of A+.
The results show margin improvement, debt reduction, and a healthy total dividend payout, which are positive signals for shareholders. However, management flagged short-term margin pressures in crop protection due to global pricing competition and macroeconomic headwinds, which could temper near-term sentiment.